Cabaletta Bio, Inc. (CABA): who owns it and who trades it
As of Nov 16, 2026, CABA insiders reported 8 purchases worth $296K in the last 12 months. The largest buyer was Steven Nichtberger (CEO), with $101K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Cabaletta Bio
From the latest filingsOverall: more buying than selling. Famous investors mostly sold. Funds and insiders mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CABA
140 funds and institutions reported CABA shares worth $494M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Jennison Associates LLC with 18.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Jennison Associates LLC | 20.03M | 18.00% | $62.3M | +123% |
| T. Rowe Price Investment Management, Inc. | 18.87M | 16.95% | $58.7M | +70% |
| Bain Capital Life Sciences Investors, LLC | 17.24M | 15.49% | $53.6M | +78% |
| BlackRock, Inc. | 10.75M | 9.66% | $33.4M | +353% |
| Adage Capital Partners Gp, L.l.c. | 9.17M | 8.24% | $28.5M | +4% |
| State Street Corp | 7.84M | 7.04% | $24.4M | +1568% |
| Vanguard Capital Management LLC | 7.23M | 6.49% | $22.5M | +79% |
| Cormorant Asset Management, LP | 5.00M | 4.49% | $15.6M | -9% |
| T. Rowe Price Associates | 4.42M | 3.97% | $13.7M | +899% |
| Woodline Partners LP | 4.20M | 3.77% | $13.1M | +236% |
| Norges Bank | 4.11M | 3.69% | $12.8M | – |
| Opaleye Management Inc. | 3.86M | 3.47% | $12M | +180% |
| Citadel Advisors LLC | 3.52M | 3.16% | $11M | – |
| Geode Capital Management, LLC | 3.46M | 3.11% | $10.8M | +205% |
| Franklin Resources Inc | 2.41M | 2.17% | $7.5M | – |
| Goldman Sachs Group Inc | 2.21M | 1.99% | $6.9M | +182% |
| Millennium Management LLC | 2.07M | 1.86% | $6.4M | -65% |
| Cantor Fitzgerald, L. P. | 1.60M | 1.44% | $5M | +109% |
| Marshall Wace, LLP | 1.57M | 1.41% | $4.9M | -28% |
| Renaissance Technologies LLC | 1.54M | 1.38% | $4.8M | -25% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CABA insiders reported $296K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jan 21, 2026 | David J. Chang | Chief Medical Officer | Purchase | 8,800 | $2.26 | $19.9K | Form 4 |
| Jan 21, 2026 | Gwendolyn Binder | President | Purchase | 11,312 | $2.19 | $24.8K | Form 4 |
| Jan 21, 2026 | Shawn Tomasello | Director | Purchase | 22,725 | $2.21 | $50.2K | Form 4 |
| Jan 21, 2026 | Steve Gavel | Chief Commercial Officer | Purchase | 22,170 | $2.27 | $50.3K | Form 4 |
| Jan 21, 2026 | Catherine Bollard | Director | Purchase | 4,405 | $2.27 | $10K | Form 4 |
| Jan 21, 2026 | Steven Nichtberger | CEO | Purchase | 45,000 | $2.24 | $101K | Form 4 |
| Jan 21, 2026 | Mark Simon | Director | Purchase | 11,061 | $2.28 | $25.2K | Form 4 |
| Jan 21, 2026 | Michael Gerard | General Counsel | Purchase | 6,600 | $2.27 | $15K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Steven Nichtberger | President & CEO, Director | $101K | – | Jan 21, 2026 |
| Steve Gavel | Chief Commercial Officer | $50.3K | – | Jan 21, 2026 |
| Shawn Tomasello | Director | $50.2K | – | Jan 21, 2026 |
| Mark Simon | Director | $25.2K | – | Jan 21, 2026 |
| Gwendolyn Binder | President, Science & Tech. | $24.8K | – | Jan 21, 2026 |
| David J. Chang | Chief Medical Officer | $19.9K | – | Jan 21, 2026 |
| Michael Gerard | General Counsel | $15K | – | Jan 21, 2026 |
| Catherine Bollard | Director | $10K | – | Jan 21, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CABA short interest
High short interest. 17.8% of CABA shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 68%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 38.37M CABA shares were sold short, 17.8% of the shares outstanding, down 2.3% from the report before. At the average daily volume of 4.68M shares, buying them all back would take about 8.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 38.37M | 17.79% | -2% | 4.68M | 8.2 |
| Oct 15, 2026 | 39.29M | 23.17% | +2% | 5.44M | 7.2 |
| Sep 30, 2026 | 38.61M | 22.77% | +16% | 6.13M | 6.3 |
| Sep 15, 2026 | 33.33M | 19.66% | -20% | 6.41M | 5.2 |
| Aug 31, 2026 | 41.44M | 24.44% | -3% | 4.96M | 8.3 |
| Aug 14, 2026 | 42.80M | 25.24% | +5% | 3.45M | 12.4 |
| Jul 31, 2026 | 40.78M | 36.63% | -1% | 2.21M | 18.4 |
| Jul 15, 2026 | 41.01M | 36.84% | +20% | 6.09M | 6.7 |
| Jun 30, 2026 | 34.06M | 30.60% | +30% | 7.86M | 4.3 |
| Jun 15, 2026 | 26.24M | 23.57% | +14% | 3.48M | 7.5 |
| May 29, 2026 | 22.94M | 20.61% | +0% | 3.02M | 7.6 |
| May 15, 2026 | 22.84M | 20.52% | +11% | 7.02M | 3.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Cabaletta Bio company events
Cabaletta Bio filed 13 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementThe Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation. Filing
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 14, 2026AnnouncementIn connection with Cabaletta Bio’s June 2025 underwritten public offering, the Corporation issued 53,090,190 common stock warrants that had an exercise price of $2.50 per whole share of its common stock and an expiration date of September 12, 2026. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- Jun 3, 2026AnnouncementThe Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation. Filing
- May 14, 2026ResultsReleased financial results. Filing
- May 14, 2026AnnouncementThe Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation. Filing
- May 4, 2026AgreementCabaletta Bio, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co., relating to an underwritten registered direct offering of 51,725,000 shares of the Company’s common stock, $0.00001 par value per share. Filing
- May 4, 2026AnnouncementCabaletta intends to present new clinical and translational data from 4 refractory patients that received rese-cel at the lowest dose without preconditioning in the RESET-PV ® (pemphigus vulgaris) trial at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, being held on May… Filing
- Apr 20, 2026AnnouncementCabaletta Bio, Inc. posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation. Filing
- Mar 23, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementThe Company posted to the “Investors & Media” section of the Company’s website at www.cabalettabio.com an updated corporate presentation. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Cabaletta Bio financials
Famous investors that hold CABA
5 of the 50 well-known investors we track reported holding CABA in their latest 13F filing. The largest position is Ken Griffin's, worth $5.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.71M | $5.2M | 0.0% | -23% |
| Israel Englander · Millennium Management | Q3 2026 | 640,361 | $1.2M | 0.0% | -69% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 272,700 | $524K | 0.0% | -82% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 78,671 | $151K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 25,719 | $49.4K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named CABA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Bain Capital Life Sciences Opportunities III, LP | 13G/A | 9.6% |
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G/A | 2.6% |
| Nov 16, 2026 | Bain Capital Life Sciences Opportunities III, LP | 13G/A | 9.6% |
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G/A | 2.6% |
| Nov 12, 2026 | Norges Bank | 13G/A | 4.0% |
| Nov 12, 2026 | Norges Bank | 13G/A | 4.0% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 8.0% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 13.1% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 8.0% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 13.1% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 3.8% |
| Oct 30, 2026 | Vanguard Capital Management | 13G/A | 3.8% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.7% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 7.7% |
Questions about Cabaletta Bio, Inc. (CABA) stock
Who owns the most CABA stock?
The largest reported owner of Cabaletta Bio, Inc. (CABA) is Jennison Associates LLC, with 18.0% of the company. In total, 140 funds and institutions reported holding CABA at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CABA insiders buying or selling?
In the last 12 months, CABA insiders reported 8 open-market purchases worth $296K and no sales. The latest trade was on Jan 21, 2026. See every trade.
What is the short interest in CABA?
As of Oct 30, 2026, 38.37M CABA shares were sold short, 17.8% of the shares outstanding, down 2.3% from the report before. At the average daily volume of 4.68M shares, buying them all back would take about 8.2 trading days (days to cover). See the history.
Which famous investors hold CABA?
5 of the 50 well-known investors we track reported CABA in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $5.2M. See all holders.
Executive pay
Cabaletta Bio's chief executive was paid a total of $1.9M for the year ended Dec 31, 2025, down 76% from $8.1M the year before. In the last 12 months, Cabaletta Bio's executives and directors bought $296K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.